Free Trial
NASDAQ:LENZ

LENZ Therapeutics (LENZ) Stock Price, News & Analysis

LENZ Therapeutics logo
$48.74 +0.42 (+0.87%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$48.35 -0.39 (-0.80%)
As of 10/3/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About LENZ Therapeutics Stock (NASDAQ:LENZ)

Advanced

Key Stats

Today's Range
$47.85
$49.85
50-Day Range
$29.33
$49.05
52-Week Range
$16.53
$50.40
Volume
325,929 shs
Average Volume
406,330 shs
Market Capitalization
$1.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.60
Consensus Rating
Moderate Buy

Company Overview

LENZ Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

LENZ MarketRank™: 

LENZ Therapeutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 887th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LENZ Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for LENZ Therapeutics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    LENZ Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about LENZ Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LENZ Therapeutics is -25.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LENZ Therapeutics is -25.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LENZ Therapeutics has a P/B Ratio of 6.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LENZ Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    20.88% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    LENZ Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LENZ Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.88% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • News Sentiment

    LENZ Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of LENZ Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LENZ Therapeutics' insider trading history.
Receive LENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LENZ Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
Jim Cramer Says “LENZ Therapeutics Has a Promising Story”
Jim Cramer’s Recent Takes on These 12 Stocks
See More Headlines

LENZ Stock Analysis - Frequently Asked Questions

LENZ Therapeutics' stock was trading at $28.87 at the start of the year. Since then, LENZ stock has increased by 68.8% and is now trading at $48.74.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) issued its quarterly earnings data on Wednesday, July, 30th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.05. The company earned $5 million during the quarter, compared to analysts' expectations of $5 million.

Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
7/30/2025
Today
10/05/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LENZ
Previous Symbol
NASDAQ:LENZ
CIK
1815776
Fax
N/A
Employees
110
Year Founded
2013

Price Target and Rating

High Price Target
$60.00
Low Price Target
$40.00
Potential Upside/Downside
+1.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.77 million
Net Margins
N/A
Pretax Margin
-1,037.94%
Return on Equity
-25.63%
Return on Assets
-24.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.54
Quick Ratio
20.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.42 per share
Price / Book
6.57

Miscellaneous

Outstanding Shares
28,520,000
Free Float
26,554,000
Market Cap
$1.39 billion
Optionable
N/A
Beta
0.50

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:LENZ) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners